Newron Pharmaceuticals – EKF interview

Published on 9 November 2020

Newron Pharmaceuticals is focused on the development of its novel schizophrenia drug with two pivotal Phase III trials due to start in Q221. The company already has a marketed product for Parkinson’s disease, Xadago, sold in Europe and the US. A further Xadago trial for the treatment of Parkinson’s dyskinesia could add to US sales and may start in 2021.

Share this with friends and colleagues